Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.93%

Ligand Pharmaceuticals reported a strong EPS performance, significantly exceeding expectations. The stock reacted positively, rising by 0.93%. Investors may view the EPS beat as a sign of operational strength, even though revenue details were not disclosed.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.40	N/A	+70.73%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to ongoing strategic projects. However, they did not provide specific guidance for future revenue.

We are pleased with our EPS performance this quarter.

While we did not provide revenue guidance, we remain focused on our strategic initiatives.

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.93%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.93%

Key numbers

Management commentary